AbbVie taps T-cell engager tech from EvolveImmune to build next-gen cancer biologics

AbbVie and EvolveImmune linked up on Thursday to develop multispecific antibody-based therapeutics for cancer using the latter's T-cell engager platform.

Under the multi-target collaboration and option agreement, AbbVie will pay $65 million upfront and is on the hook for up to $1.4 billion in option fees and milestones, plus royalties.